UNSPSC 51142541: Amantadine sulfate

This classification denotes a miscellaneous antiviral agent and cation channel blocker with the molecular formula 2C10H17N.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9921T5P019. European Medicines Agency schedules amantadine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00423MIG. The term amantadine sulfate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule amantadine sulfate under HS 29213099 and SITC 51453.

As of Q4 2014, AMANTADINE SULFATE remains US FDA's Preferred Term for this commodity. Amantadine sulfate bears US NLM identifiers UMLS ID C0002404 and NCI Concept Code C90781. SMILES: C1C2CC3CC1CC(C2)(C3)N.OS(=O)(=O)O.

UNSPSC 51142541 Amantadine sulfate is a Commodity code for pharmaceutical active ingredients, but the recent state and local solicitation activity tagged to it does not reflect pharmaceutical procurement. Seminole County, Florida posted an IFB on June 30, 2026 (IFB60459723LAS) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The code shows little relevant recent activity; the single sourced opportunity addresses emergency medical supplies and harm-reduction equipment rather than the pharmaceutical manufacturing or distribution inputs the code's title implies.

Seminole County is the sole issuing body in the recent record. The IFB response date was July 26, 2023 (note the discrepancy with the posted date of June 30, 2026 in the source), with a probationary three-month contract term and an initial two-year agreement plus one-year renewal option. Vendors must provide unit costs for each line item, comply with drug-free workplace certification and E-Verify requirements, and maintain workers' compensation, commercial general liability, and professional liability insurance. The procurement does not specify set-aside designations and notes potential FEMA funding with corresponding federal compliance obligations. Because the code's nominal scope and the actual solicitation are misaligned, pursue this code only if your firm supplies Naloxone or drug deactivation systems to public health agencies; if your business focuses on pharmaceutical raw materials or active ingredient supply, the code does not reflect current state and local buying patterns.